Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afn-1252. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afn-1252 SCHEMBL29603927 | 1.00 | — | — | |
| Afn-1252 SCHEMBL726875 | 1.00 | — | — | |
| Afn-1252 SCHEMBL724937 | 1.00 | — | — | |
| Afn-1252 SCHEMBL29378725 | 1.00 | — | — | |
| Afn-1252 SCHEMBL726106 | 0.99 | — | — | |
| Afn-1252 SCHEMBL724646 | 0.99 | — | — | |
| Afn-1252 SCHEMBL724647 | 0.99 | — | — | |
| Afn-1252 SCHEMBL726107 | 0.99 | — | — | |
| Afn-1252 SCHEMBL726232 | 0.97 | — | — | |
| Afn-1252 SCHEMBL4114471 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| WO-2024189127-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | PROLEVI BIO AB (SE) | 2024-09-19 | — | — | WO | claimed |
| EP-3419628-B1 | MEDICAMENT FOR TREATMENT OF DIABETIC FOOT INFECTIONS | DEBIOPHARM INT SA (CH) | 2020-10-14 | — | — | EP | claimed |
| US-10751351-B2 | Medicament for treatment of diabetic foot infections | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-08-25 | — | — | US | claimed |
| EP-2861608-B1 | PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE | DEBIOPHARM INT SA (CH) | 2019-04-24 | — | — | EP | claimed |
| EP-2861608-A1 | PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE | Debiopharm International SA (CH) | 2015-04-22 | — | — | EP | claimed |
| US-8901105-B2 | Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-12-02 | — | — | US | claimed |
| US-20140051666-A1 | PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-02-20 | — | — | US | claimed |
| WO-2013190384-A1 | PRODRUG DERIVATIVES OF (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-12-27 | — | — | WO | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | claimed |
| US-20090042927-A1 | Salts, Prodrugs and Polymorphs of Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-02-12 | — | — | US | claimed |
| EP-1560584-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-01-14 | — | — | EP | claimed |
| WO-2008098374-A1 | SALTS, PRODRUGS AND POLYMORPHS OF FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2008-08-21 | — | — | WO | claimed |
| US-7250424-B2 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-07-31 | — | — | US | claimed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | claimed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | claimed |
| EP-1560584-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-10-12 | — | — | EP | claimed |
| EP-1560584-A2 | FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2005-08-10 | — | — | EP | claimed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | claimed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | claimed |